Therefore, with the findings that these TCR clones were associated with favorable clinical outcomes in patients with an EGFR mutation with NSCLC, we suggest that the identified 4 TCR clones might have an antitumor response in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.